Pharmigene, Inc. (TPEX:7595)

Pharmigene Statistics

Total Valuation

Pharmigene has a market cap or net worth of TWD 577.82 million. The enterprise value is 1.04 billion.

Market Cap	577.82M
Enterprise Value	1.04B

Important Dates

The next estimated earnings date is Friday, August 8, 2025.

Earnings Date	Aug 8, 2025
Ex-Dividend Date	n/a

Share Statistics

Pharmigene has 50.47 million shares outstanding. The number of shares has increased by 10.96% in one year.

Current Share Class	50.47M
Shares Outstanding	50.47M
Shares Change (YoY)	+10.96%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	7.32%
Owned by Institutions (%)	n/a
Float	32.27M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.96
PB Ratio	1.66
P/TBV Ratio	1.72
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-12.50
EV / Sales	8.89
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-9.46

Financial Position

The company has a current ratio of 4.77, with a Debt / Equity ratio of 1.77.

Current Ratio	4.77
Quick Ratio	3.28
Debt / Equity	1.77
Debt / EBITDA	n/a
Debt / FCF	-5.63
Interest Coverage	-7.04

Financial Efficiency

Return on equity (ROE) is -20.89% and return on invested capital (ROIC) is -5.38%.

Return on Equity (ROE)	-20.89%
Return on Assets (ROA)	-5.20%
Return on Invested Capital (ROIC)	-5.38%
Return on Capital Employed (ROCE)	-8.97%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.11
Inventory Turnover	1.85

Taxes

In the past 12 months, Pharmigene has paid 35,000 in taxes.

Income Tax	35,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -36.39% in the last 52 weeks. The beta is 0.12, so Pharmigene's price volatility has been lower than the market average.

Beta (5Y)	0.12
52-Week Price Change	-36.39%
50-Day Moving Average	12.27
200-Day Moving Average	13.53
Relative Strength Index (RSI)	35.69
Average Volume (20 Days)	4,271

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Pharmigene had revenue of TWD 116.53 million and -82.86 million in losses. Loss per share was -1.64.

Revenue	116.53M
Gross Profit	41.47M
Operating Income	-85.23M
Pretax Income	-82.83M
Net Income	-82.86M
EBITDA	-65.21M
EBIT	-85.23M
Loss Per Share	-1.64

Balance Sheet

The company has 158.64 million in cash and 616.49 million in debt, giving a net cash position of -457.84 million or -9.07 per share.

Cash & Cash Equivalents	158.64M
Total Debt	616.49M
Net Cash	-457.84M
Net Cash Per Share	-9.07
Equity (Book Value)	349.06M
Book Value Per Share	6.92
Working Capital	197.74M

Cash Flow

In the last 12 months, operating cash flow was -44.82 million and capital expenditures -64.60 million, giving a free cash flow of -109.42 million.

Operating Cash Flow	-44.82M
Capital Expenditures	-64.60M
Free Cash Flow	-109.42M
FCF Per Share	-2.17

Margins

Gross margin is 35.59%, with operating and profit margins of -73.13% and -71.11%.

Gross Margin	35.59%
Operating Margin	-73.13%
Pretax Margin	-71.08%
Profit Margin	-71.11%
EBITDA Margin	-55.96%
EBIT Margin	-73.13%
FCF Margin	n/a

Dividends & Yields

Pharmigene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.96%
Shareholder Yield	n/a
Earnings Yield	-14.34%
FCF Yield	-18.94%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Pharmigene has an Altman Z-Score of 0.53 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.53
Piotroski F-Score	2